Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
1. Silexion's SIL-204 shows significant synergy with key pancreatic cancer drugs. 2. Preclinical tests indicate improved efficacy of SIL-204 with chemotherapy agents. 3. A public offering of 3.7 million shares raises $5 million for Silexion. 4. Silexion aims to progress SIL-204 to clinical trials by mid-2026. 5. SLXN shares recently experienced a 42.96% decline.